Biohaven Ltd. (BHVN) Q1 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. Welcome to the BioHaven Pharmaceuticals Q1 2021 earnings call. At this time, all participant lines are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please be advised that today's conference call may be recorded. I would now like to hand the conference over to Clifford Bechtold from Biohaven. Biohaven, thank you, and please go ahead. Thank you, and good morning to everybody. And welcome to the Biohaven first quarter 2021 earnings call. Speaking on today's call are Dr. Vlad Torch, our chief executive officer, Jim Englehart, chief financial officer, BJ Jones, chief commercial officer, and Dr. Elise Stock, our chief medical officer. Earlier this morning, we issued a press release announcing the first quarter of 2021 highlights. A copy of this press release can be found on our website at biohavenfarmer.com, and we will file our Form 10-Q later today. Before we begin, let me remind everybody that today's discussion contains forward-looking statements based on the environment as we currently see it, and includes risks and uncertainties. A list and description of the risks and uncertainties associated with an investment in Biohaven can be found in the company's filing with the U.S. Securities and Exchange Commission. Please be aware that you should not place undue reliance on the forward-looking statements we make today. For this call, we will focus on non-GAAP financial measures with detailed descriptions of GAAP and non-GAAP analysis in our filings. An archive of today's call will be posted to the Biohaven's website in the investor relations section. With that, I will turn the call over t...